Related references
Note: Only part of the references are listed.An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry
L. Couchman et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2012)
Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study
Mitchell E. Gross et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma
Lutz Goetze et al.
CLINICA CHIMICA ACTA (2012)
Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph plus chronic myeloid leukemia in chronic phase
Richard A. Larson et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
The Role of Therapeutic Drug Monitoring of Imatinib in Patients with Chronic MyeloidLeukemiaandMetastatic or Unresectable Gastrointestinal Stromal Tumors
Jennifer F. T. Teng et al.
THERAPEUTIC DRUG MONITORING (2012)
Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS
Stephane Bouchet et al.
CLINICA CHIMICA ACTA (2011)
Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics
Thomas Yau et al.
CLINICAL CANCER RESEARCH (2011)
Determination of Sunitinib and Its Active Metabolite N-Desethylsunitinib in Sweat of a Patient
Nienke A. G. Lankheet et al.
JOURNAL OF ANALYTICAL TOXICOLOGY (2011)
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
Brett E. Houk et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry
R. Honeywell et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2010)
Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry
Peter de Bruijn et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2010)
New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma
Silvia De Francia et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2009)
A high-performance liquid chromatography-mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum
Robert A. Parise et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2009)
Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma
Rolf W. Sparidans et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2009)
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry
A. Haouala et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2009)
Hydrophilic interaction liquid chromatography/tandem mass spectrometry for the simultaneous determination of dasatinib, imatinib and nilotinib in mouse plasma
Yunsheng Hsieh et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2009)
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
Richard A. Larson et al.
BLOOD (2008)
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
N. Widmer et al.
BRITISH JOURNAL OF CANCER (2008)
Importance of Characterizing Determinants of Variability in Exposure: Application to Dasatinib in Subjects With Chronic Myeloid Leukemia
Guowei Dai et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Current and emerging tests for the laboratory monitoring of chronic myeloid leukaemia and related disorders
D. M. Ross et al.
PATHOLOGY (2008)
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Jane F. Apperley
LANCET ONCOLOGY (2007)
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
Stephane Picard et al.
BLOOD (2007)
The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry
Andrea R. Masters et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2007)
A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay
Ming Zhao et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2007)
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors
Dirk Strumberg et al.
ONCOLOGIST (2007)
Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors
Catherine Delbaldo et al.
CLINICAL CANCER RESEARCH (2006)
Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS)
F Bai et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2006)
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
HA Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Tyrosine kinases as targets for cancer therapy
DS Krause et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry
M Zhao et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2005)
High-throughput quantification of the anti-leukemia drug ST1571 (Gleevec™) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry
R Bakhtiar et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2002)
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
M Hidalgo et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
